Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response

14 Sept 2009

Abstract excerpt

This study evaluated the preclinical activity and molecular predictors of response to gefitinib (Iressa(R), Astra Zeneca Inc, UK) in nasopharyngeal carcinoma (NPC). The activity of gefitinib was evaluated in four human NPC cell lines--HK1, HONE-1, CNE2, C666-1. A representative gefitinib-sensitive (HK1, IC(50) = 250 nM) and gefitinib-resistant cell line (HONE-1, IC(50) > 15 microM) were selected and compared for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related gene regulation
Share to Lung Cancer Treatments and Mutations
Share to Pancreatic and Hepatic Oncology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19756373
DOI: 10.1007/s10637-009-9316-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of responsePMID 19756373Read ↗

MiRNA-125a-5p: a regulator and predictor of gefitinib’s effect on nasopharyngeal carcinomaSemantic proximity Read ↗

Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma (Review)Semantic proximity Read ↗

Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition.Semantic proximity Read ↗

Validation of gefitinib effectiveness in a broad panel of head and neck squamous carcinoma cells.Semantic proximity Read ↗

A 3D Bioprinted Spheroid Model of Nasopharyngeal Carcinoma Uncovers Constitutive IGF‑1R/PI3K/AKT Signaling as a Mediator of Intrinsic Cetuximab Resistance and a Therapeutic VulnerabilitySemantic proximity Read ↗

Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.Semantic proximity Read ↗

Acquisition of EMT phenotype in the gefitinib-resistant cells of a head and neck squamous cell carcinoma cell line through Akt/GSK-3β/snail signalling pathway.Semantic proximity Read ↗

Investigational drugs for nasopharyngeal carcinoma.Semantic proximity Read ↗

Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer&nbsp;in&nbsp;vitro and in vivoSemantic proximity Read ↗

Molecular pathways in head and neck cancer: EGFR, PI3K, and more.Semantic proximity Read ↗

Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition.Semantic proximity Read ↗

Therapeutic evaluation of palbociclib and its compatibility with other chemotherapies for primary and recurrent nasopharyngeal carcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.